Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 143


Membrane-Bound PenA β-Lactamase of Burkholderia pseudomallei.

Randall LB, Dobos K, Papp-Wallace KM, Bonomo RA, Schweizer HP.

Antimicrob Agents Chemother. 2015 Dec 28;60(3):1509-14. doi: 10.1128/AAC.02444-15.


Absence of Bacteria in the Temporal Arteries of Patients with Giant Cell Arteritis.

Koening CL, Peterson SG, Podnecky NL, Schweizer HP, Li DY, Katz BJ.

J Clin Rheumatol. 2016 Jan;22(1):43-4. doi: 10.1097/RHU.0000000000000344. No abstract available.


Exposing a β-Lactamase "Twist": the Mechanistic Basis for the High Level of Ceftazidime Resistance in the C69F Variant of the Burkholderia pseudomallei PenI β-Lactamase.

Papp-Wallace KM, Becka SA, Taracila MA, Winkler ML, Gatta JA, Rholl DA, Schweizer HP, Bonomo RA.

Antimicrob Agents Chemother. 2015 Nov 23;60(2):777-88. doi: 10.1128/AAC.02073-15.


Precision-engineering the Pseudomonas aeruginosa genome with two-step allelic exchange.

Hmelo LR, Borlee BR, Almblad H, Love ME, Randall TE, Tseng BS, Lin C, Irie Y, Storek KM, Yang JJ, Siehnel RJ, Howell PL, Singh PK, Tolker-Nielsen T, Parsek MR, Schweizer HP, Harrison JJ.

Nat Protoc. 2015 Nov;10(11):1820-41. doi: 10.1038/nprot.2015.115. Epub 2015 Oct 22.


Pseudomonas aeruginosa: arsenal of resistance mechanisms, decades of changing resistance profiles, and future antimicrobial therapies.

El Zowalaty ME, Al Thani AA, Webster TJ, El Zowalaty AE, Schweizer HP, Nasrallah GK, Marei HE, Ashour HM.

Future Microbiol. 2015;10(10):1683-706. doi: 10.2217/fmb.15.48. Epub 2015 Oct 6.


Efflux pump-mediated drug resistance in Burkholderia.

Podnecky NL, Rhodes KA, Schweizer HP.

Front Microbiol. 2015 Apr 14;6:305. doi: 10.3389/fmicb.2015.00305. eCollection 2015.


A Burkholderia pseudomallei colony variant necessary for gastric colonization.

Austin CR, Goodyear AW, Bartek IL, Stewart A, Sutherland MD, Silva EB, Zweifel A, Vitko NP, Tuanyok A, Highnam G, Mittelman D, Keim P, Schweizer HP, Vázquez-Torres A, Dow SW, Voskuil MI.

MBio. 2015 Feb 3;6(1). pii: e02462-14. doi: 10.1128/mBio.02462-14.


Tn5/7-lux: a versatile tool for the identification and capture of promoters in gram-negative bacteria.

Bruckbauer ST, Kvitko BH, Karkhoff-Schweizer RR, Schweizer HP.

BMC Microbiol. 2015 Feb 4;15:17. doi: 10.1186/s12866-015-0354-3.


Blocking phosphatidylcholine utilization in Pseudomonas aeruginosa, via mutagenesis of fatty acid, glycerol and choline degradation pathways, confirms the importance of this nutrient source in vivo.

Sun Z, Kang Y, Norris MH, Troyer RM, Son MS, Schweizer HP, Dow SW, Hoang TT.

PLoS One. 2014 Jul 28;9(7):e103778. doi: 10.1371/journal.pone.0103778. eCollection 2014.


Rapid Burkholderia pseudomallei identification and antibiotic resistance determination by bacteriophage amplification and MALDI-TOF MS.

Cox CR, Saichek NR, Schweizer HP, Voorhees KJ.

Bacteriophage. 2014 Apr 25;4:e29011. eCollection 2014.


New insights from the 7th World Melioidosis Congress 2013.

Schweizer HP, Limmathurotsakul D, Peacock SJ.

Emerg Infect Dis. 2014 Jul;20(7). doi: 10.3201/eid2007.131737. No abstract available.


Substituted diphenyl ethers as a novel chemotherapeutic platform against Burkholderia pseudomallei.

Cummings JE, Beaupre AJ, Knudson SE, Liu N, Yu W, Neckles C, Wang H, Khanna A, Bommineni GR, Trunck LA, Schweizer HP, Tonge PJ, Slayden RA.

Antimicrob Agents Chemother. 2014;58(3):1646-51. doi: 10.1128/AAC.02296-13. Epub 2013 Dec 30.


The Burkholderia pseudomallei enoyl-acyl carrier protein reductase FabI1 is essential for in vivo growth and is the target of a novel chemotherapeutic with efficacy.

Cummings JE, Kingry LC, Rholl DA, Schweizer HP, Tonge PJ, Slayden RA.

Antimicrob Agents Chemother. 2014;58(2):931-5. doi: 10.1128/AAC.00176-13. Epub 2013 Nov 25.


Polar lipids of Burkholderia pseudomallei induce different host immune responses.

Gonzalez-Juarrero M, Mima N, Trunck LA, Schweizer HP, Bowen RA, Dascher K, Mwangi W, Eckstein TM.

PLoS One. 2013 Nov 18;8(11):e80368. doi: 10.1371/journal.pone.0080368. eCollection 2013.


Correlates of immune protection following cutaneous immunization with an attenuated Burkholderia pseudomallei vaccine.

Silva EB, Goodyear A, Sutherland MD, Podnecky NL, Gonzalez-Juarrero M, Schweizer HP, Dow SW.

Infect Immun. 2013 Dec;81(12):4626-34. doi: 10.1128/IAI.00915-13. Epub 2013 Oct 7.


An improved selective culture medium enhances the isolation of Burkholderia pseudomallei from contaminated specimens.

Goodyear A, Strange L, Rholl DA, Silisouk J, Dance DA, Schweizer HP, Dow S.

Am J Trop Med Hyg. 2013 Nov;89(5):973-82. doi: 10.4269/ajtmh.13-0119. Epub 2013 Sep 23.


High-level pacidamycin resistance in Pseudomonas aeruginosa is mediated by an opp oligopeptide permease encoded by the opp-fabI operon.

Mistry A, Warren MS, Cusick JK, Karkhoff-Schweizer RR, Lomovskaya O, Schweizer HP.

Antimicrob Agents Chemother. 2013 Nov;57(11):5565-71. doi: 10.1128/AAC.01198-13. Epub 2013 Aug 26.


The BpeEF-OprC efflux pump is responsible for widespread trimethoprim resistance in clinical and environmental Burkholderia pseudomallei isolates.

Podnecky NL, Wuthiekanun V, Peacock SJ, Schweizer HP.

Antimicrob Agents Chemother. 2013 Sep;57(9):4381-6. doi: 10.1128/AAC.00660-13. Epub 2013 Jul 1.


Does microbicide use in consumer products promote antimicrobial resistance? A critical review and recommendations for a cohesive approach to risk assessment.

Maillard JY, Bloomfield S, Coelho JR, Collier P, Cookson B, Fanning S, Hill A, Hartemann P, McBain AJ, Oggioni M, Sattar S, Schweizer HP, Threlfall J.

Microb Drug Resist. 2013 Oct;19(5):344-54. doi: 10.1089/mdr.2013.0039. Epub 2013 Jun 14. Review.


An improved method for oriT-directed cloning and functionalization of large bacterial genomic regions.

Kvitko BH, McMillan IA, Schweizer HP.

Appl Environ Microbiol. 2013 Aug;79(16):4869-78. doi: 10.1128/AEM.00994-13. Epub 2013 Jun 7.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk